Maze Therapeutics, Common Stock Net Income
| MAZE Stock | 40.88 0.00 0.00% |
Fundamental analysis of Maze Therapeutics, allows traders to better anticipate movements in Maze Therapeutics,'s stock price by examining its financial health and performance throughout various phases of its business cycle.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 52.2 M | 54.8 M | |
| Net Income | 52.2 M | 54.8 M | |
| Net Income Per Share | 1.19 | 1.25 | |
| Net Income Per E B T | 0.88 | 0.78 |
Maze Therapeutics, Common Company Net Income Analysis
Maze Therapeutics,'s Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Maze Therapeutics, Net Income | 52.23 M |
Most of Maze Therapeutics,'s fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Maze Therapeutics, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Maze Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Maze Therapeutics, is extremely important. It helps to project a fair market value of Maze Stock properly, considering its historical fundamentals such as Net Income. Since Maze Therapeutics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Maze Therapeutics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Maze Therapeutics,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Maze Net Interest Income
Net Interest Income |
|
Based on the recorded statements, Maze Therapeutics, Common reported net income of 52.23 M. This is 84.7% lower than that of the Pharmaceuticals sector and 25.43% lower than that of the Health Care industry. The net income for all United States stocks is 90.85% higher than that of the company.
Maze Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Maze Therapeutics,'s direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Maze Therapeutics, could also be used in its relative valuation, which is a method of valuing Maze Therapeutics, by comparing valuation metrics of similar companies.Maze Therapeutics, is currently under evaluation in net income category among its peers.
Maze Therapeutics, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Maze Therapeutics,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Maze Therapeutics,'s managers, analysts, and investors.Environmental | Governance | Social |
Maze Fundamentals
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 1.67 B | ||||
| Shares Outstanding | 48.12 M | ||||
| Shares Owned By Insiders | 1.88 % | ||||
| Shares Owned By Institutions | 86.22 % | ||||
| Number Of Shares Shorted | 2.22 M | ||||
| Price To Book | 5.34 X | ||||
| Price To Sales | 3.14 X | ||||
| Revenue | 167.5 M | ||||
| EBITDA | 60.88 M | ||||
| Net Income | 52.23 M | ||||
| Total Debt | 26.63 M | ||||
| Book Value Per Share | 7.89 X | ||||
| Cash Flow From Operations | 75.95 M | ||||
| Short Ratio | 5.37 X | ||||
| Earnings Per Share | (2.56) X | ||||
| Target Price | 46.56 | ||||
| Number Of Employees | 125 | ||||
| Market Capitalization | 2.03 B | ||||
| Total Asset | 240.54 M | ||||
| Retained Earnings | (358.43 M) | ||||
| Working Capital | 181 M | ||||
| Net Asset | 240.54 M |
About Maze Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Maze Therapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Maze Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Maze Therapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Maze Therapeutics, Common is a strong investment it is important to analyze Maze Therapeutics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Maze Therapeutics,'s future performance. For an informed investment choice regarding Maze Stock, refer to the following important reports:Check out Maze Therapeutics, Piotroski F Score and Maze Therapeutics, Altman Z Score analysis. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Maze Therapeutics,. If investors know Maze will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Maze Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Maze Therapeutics, Common is measured differently than its book value, which is the value of Maze that is recorded on the company's balance sheet. Investors also form their own opinion of Maze Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Maze Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Maze Therapeutics,'s market value can be influenced by many factors that don't directly affect Maze Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Maze Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Maze Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Maze Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.